A5058269745- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Mosquito-borne diseases and control
- Sepsis Diagnosis and Treatment
- Virology and Viral Diseases
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Monoclonal and Polyclonal Antibodies Research
- Viral Infections and Vectors
- Clostridium difficile and Clostridium perfringens research
- SARS-CoV-2 and COVID-19 Research
- Immune Response and Inflammation
- Hepatitis B Virus Studies
- Complement system in diseases
- Hepatitis C virus research
- Renal Transplantation Outcomes and Treatments
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Antimicrobial Resistance in Staphylococcus
- Chemokine receptors and signaling
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood disorders and treatments
- Pharmaceutical studies and practices
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood groups and transfusion
Medical University of Vienna
2016-2025
Vienna General Hospital
2020-2022
Intercell (Austria)
2007
St. James's Hospital
2006
Sapporo Kosei General Hospital
2006
Nishikawa Hospital
2006
Late antibody-mediated rejection (ABMR) is a leading cause of transplant failure. Blocking IL-6 has been proposed as promising therapeutic strategy.
IC43 is a recombinant outer membrane protein-based vaccine against Pseudomonas aeruginosa (P. aeruginosa) consisting of OprF- and OprI- epitopes (Opr, protein; OprF/I, OprF/OprI hybrid vaccine) with an N-terminal His 6 tag (Met-Ala-(His)6-OprF190-342-OprI21-83).The study aimed to confirm the optimal dose in adults regard immunogenicity, safety, tolerability after vaccination three different dosages IC43, compared placebo, investigate potential immune-enhancing effect adjuvant, aluminum...
The classical pathway (CP) of complement may contribute to the pathogenesis antibody-mediated rejection (ABMR). Selective CP blockade be a promising strategy counteract rejection. objective this first-in-patient phase 1b trial was evaluate safety/tolerability and CP-blocking potential 4 weekly doses (60 mg/kg) anti-C1s antibody BIVV009 in complement-mediated disorders. Here we describe results cohort 10 stable kidney transplant recipients (median 4.3 years posttransplantation) with late...
Late antibody-mediated rejection (ABMR) triggered by donor-specific antibodies (DSA) is a cardinal cause of kidney allograft dysfunction and loss. Diagnostic criteria for this type are well established, but effective treatment remains major challenge. Recent randomized controlled trials (RCT) have failed to demonstrate the efficacy widely used therapies, such as rituximab plus intravenous immunoglobulin or proteasome inhibition (bortezomib), reinforcing great need new therapeutic concepts....
Japanese encephalitis (JE) is the most important mosquito-borne viral and has a high case fatality rate. It caused by virus. Improved vaccines are urgently needed for residents in countries of endemicity, travelers, military. The aim present trial was to evaluate safety tolerability IC51, Intercell's Vero cell-derived, purified, inactivated JE vaccine.This randomized (3:1), double-blind, placebo-controlled, multicenter phase 3 trial. Healthy subjects were receive 2 doses IC51 (n=2012) or...
ASN100 is a novel antibody combination of two fully human IgG1(κ) monoclonal antibodies (MAbs), ASN-1 and ASN-2, which neutralize six Staphylococcus aureus cytotoxins, alpha-hemolysin (Hla) five bicomponent leukocidins. We assessed the safety, tolerability, serum lung pharmacokinetics in randomized, double-blind, placebo-controlled single-dose-escalation first-in-human study.
Aberrant activation of the classical complement pathway is common underlying pathophysiology orphan diseases such as bullous pemphigoid, antibody-mediated rejection organ transplants, cold agglutinin disease, and warm autoimmune hemolytic anemia. Therapeutic options for these complement-mediated disorders are limited sutimlimab, a humanized monoclonal antibody directed against factor C1s, may be potentially useful inhibition pathway. A phase I, first-in-human, double-blind, randomized,...
ObjectiveTo investigate the immunogenicity and safety of BNT162b2 booster vaccination with without a tetravalent influenza vaccine.MethodsA prospective, open-label cohort study on COVID-19 or vaccine was performed. Eight hundred thirty-eight health care workers were included in following arms: booster-only, influenza-vaccine-only combination both. Levels antibodies against SARS-CoV-2 spike receptor binding domain, haemagglutinin inhibition tested for four different strains (A(H1N1)pdm09,...
BackgroundToxic shock syndrome toxin-1 (TSST-1) is a superantigen produced by Staphylococcus aureus that causes the life-threatening toxic syndrome. The development of safe and immunogenic vaccine against TSST-1 remains an unmet medical need. We investigated safety, tolerability immunogenicity recombinant variant (rTSST-1v) after 1–3 injections in healthy volunteers.MethodsIn this randomised, double-blind, adjuvant-controlled, parallel-group, phase 2 trial, adults aged 18–64 were randomly...
2-deoxy-D-glucose is a synthetic glucose analog and potent inhibitor of glycolysis. Preclinical models demonstrated antiviral effects by inducing glucose-deprived state in cells, which interferes with viral replication. This was phase I, first-in-human, double-blind, randomized, placebo-controlled, dose-escalation trial single (cohort 1: 100µl one nostril, cohort 2: 200µl 3: both nostrils) multiple 4: four-times 200µl/day 5: nostrils, 6: six-times nostrils; all for seven days) ascending...
Objective: The Duffy receptor is a promiscuous for chemokines and selectively binds CXC CC with high affinity. Preclinical data show that presence of the on red blood cells may influence plasma levels proinflammatory cytokines be protective during inflammation. This trial was designed to investigate antigen human inflammation in vivo. Design: Prospective, analyst-blinded clinical trial. Patients: A total 32 healthy male volunteers: 16 Duffy-positive white subjects Duffy-negative African...
Granulocyte colony-stimulating factor (G-CSF) stimulates the bone marrow to produce granulocytes and stem cells is widely used accelerate neutrophil recovery after chemotherapy. Interestingly, specific G-CSF receptors have been demonstrated not only on myeloid cells, but also platelets. Data effects of platelet function are limited partly conflicting. The objective this study was determine effect aggregation in vivo activation. Seventy-eight, healthy volunteers were enrolled into randomised,...
Von Willebrand factor (VWF) and VIII (FVIII) circulate in a noncovalent complex blood promote primary hemostasis clotting, respectively. A new VWF A1-domain binding aptamer, BT200, demonstrated good subcutaneous bioavailability long half-life non-human primates. This first-in-human, randomized, placebo-controlled, doubleblind trial tested the hypothesis that BT200 is well tolerated has favorable pharmacokinetic pharmacodynamic effects 112 volunteers. Participants received one of following:...
Abstract Background Antibody-mediated rejection (ABMR) is a cardinal cause of renal allograft loss. This type, which may occur at any time after transplantation, commonly presents as continuum microvascular inflammation (MVI) culminating in chronic tissue injury. While the clinical relevance ABMR well recognized, its treatment, particularly long has remained big challenge. A promising strategy to counteract be use CD38-directed treatment deplete alloantibody-producing plasma cells (PC) and...
We hypothesized that infusion of recombinant human antithrombin without concomitant heparin would have dose-dependent anticoagulant properties and potentially decrease endotoxin (lipopolysaccharide [LPS])–induced cytokine production. This was a randomized, double-blind, placebo-controlled study in parallel groups enrolling 30 healthy male volunteers. The active treatment received infusions to increase levels 200% 500% before 2 ng/kg (LPS). Infusion dose-dependently decreased coagulation...